Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Dutasteride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 31 Prostatic Hyperplasia 5 Neoplasms 4 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 1 1 Lower Urinary Tract Symptoms 1 Erectile Dysfunction 1 Adenocarcinoma of the Prostate 1

Interventions

Cyclophosphamide 152 Dexamethasone 140 Rituximab 84 fludarabine 79 Lenalidomide 72 Cytarabine 70 fludarabine phosphate 63 Bortezomib 63 Gemcitabine 62 venetoclax 54 Etoposide 53 pomalidomide 51 pembrolizumab 51 Paclitaxel 48 Cisplatin 48 Carboplatin 48 Peripheral Blood Stem Cell Transplantation 47 Filgrastim 40 Radiotherapy 39 Busulfan 37 Calcium Dobesilate 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 30 Nivolumab 29 Bendamustine Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡